KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.

Eric S Rovner, Janet Owens-Grillo, Elizabeth Thomas, Sender Herschorn, Kenneth M Peters, David Staskin, Salim Mujais

Neurourol Urodyn 45(2) 299-304

PMID41363221
PMCIDPMC12893031
DOI10.1002/nau.70199
发表日期2025-12-09
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图。
摘要

摘要

PURPOSE: Vibegron was associated with improvements in efficacy versus placebo and was well tolerated in men with overactive bladder (OAB) on pharmacotherapy for benign prostatic hyperplasia (BPH) in the COURAGE trial (NCT03902080). Additional safety, bladder function, and urodynamics data are provided. METHODS: This 24-week, phase 3, double-blind, placebo-controlled trial randomized men ≥ 45 years with OAB and BPH receiving α-blocker ± 5α-reductase inhibitors to once-daily vibegron or placebo (1:1). From the safety analysis set (SAF), postvoid residual urine volume (PVR), maximum urinary flow rate (Uroflow-Qmax), International Prostate Symptom Score (IPSS) total score, and urologic-related adverse events (AEs) were collected throughout the trial. Qmax and detrusor pressure at Qmax (PdetQmax) were collected at baseline and week 12 in a urodynamics substudy (urodynamics evaluable set [UES]). RESULTS: In the SAF, differences between vibegron (n = 553) and placebo (n = 551) in PVR and Uroflow-Qmax were minimal at baseline, week 12, and week 24. Mean (SD) change from baseline (CFB) at week 24 in IPSS total score was -7.3 (6.96) with vibegron and -5.7 (7.14) with placebo. Urinary retention was reported as an AE for 5 (0.9%) and 4 (0.7%) participants receiving vibegron and placebo, respectively. In the UES (vibegron, n = 21; placebo, n = 22), least squares mean difference (95% CI) between vibegron and placebo in CFB at week 12 was 2.75 (0.16, 5.34) mL/s in Qmax and 2.86 (-13.52, 19.25) cmH2O in PdetQmax. CONCLUSIONS: There were no safety signals related to bladder function identified by urodynamics; risk of protocol-defined AEs of urinary retention or residual urine volume increase was not increased with vibegron compared with placebo in this population. CLINICAL TRIAL REGISTRATION: This study is registered at www. CLINICALTRIALS: gov. The registration identification number is NCT03902080.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1LS mean change from baseline for (A) PVR and (B) Uroflow Q max in the SAF at week 24. The SAF consists of all participants who received ≥ 1 dose of the double‐blind study medication. BL, baseline; LS, least squares; LSMD, LS mean difference; PVR, postvoid residual urine volume; SAF, safety analysis set; Q max , maximum urinary flow rate.
非 KM Figure
FIGURE 2LS mean change from baseline at week 12 for (A) Q max and (B) P det Q max in the UES. The UES consists of all participants randomized to the urodynamic substudy who received ≥ 1 dose of the double‐blind study treatment and had both measures at baseline and ≥ 1 measurement at 12 weeks. LS, least squares; LSMD, LS mean difference; P det Q max , detrusor pressure at peak flow rate; Q max , peak flow rate; UES, urodynamic evaluable set.
非 KM Figure